Clinical Sales Specialist

Corcept Therapeutics reported Q1 revenues of $164.9 million, up 4.9% year on year, but missed analysts' expectations by 11.3%. Despite the significant miss on earnings per share estimates, the stock has surged 107% since reporting and currently trades at $96.50, achieving the highest full-year guidance raise amongst its peers. The branded pharmaceuticals sector reported mixed Q1 results, with the 10 tracked stocks beating consensus revenue estimates by 3.6% on average. Share prices have risen 8.5% on average since earnings. Eli Lilly led the group with revenues of $19.8 billion, up 55.5% year on year, exceeding expectations by 13.7%. The stock has climbed 40.7% since reporting to $1,197.

Corcept Therapeutics Q2 earnings call highlights. July 29, 2026 Key points. * Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing's syndrome business and $47.6 million from newly launched ovarian cancer drug LIFYORLI. Corcept raised its 2026 revenue guidance to $1.1 billion-$1.2 billion. * LIFYORLI's launch is gaining traction, with more than 1,300 patients treated, over 1,000 prescribing physicians and coverage policies for more than 70% of relevant insured lives. Corcept expects the therapy's U.S. revenue in platinum-resistant ovarian cancer to eventually exceed $1 billion annually. * The FDA accepted Corcept's resubmitted relacorilant application for Cushing's syndrome and set a December 17, 2026, action date, while pipeline studies continue in cancer, MASH and ALS. * Five stocks we like better than Corcept Therapeutics. Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability. Net income rose to $43 million from $35 million a year earlier. Chief Financial Officer Atabak Mokari said operating expenses were flat compared with the first quarter, while cash and investments totaled $545 million as of June 30. The company raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Mokari said the updated outlook reflects strength in both Corcept's endocrinology and oncology businesses. LIFYORLI launch drives oncology growth. Corcept's LIFYORLI, approved by the FDA on March 25 for platinum-resistant ovarian cancer, generated $47.6 million in revenue after the company began selling the treatment April 1. Roberto Vieira, president of Corcept's oncology division, described the launch as one of the strongest for an oncology medication. Vieira said more than 1,300 patients have started treatment with LIFYORLI and more than 1,000 physicians have prescribed it to at least one patient. He said demand has come from academic and non-teaching hospitals as well as community oncology clinics. According to the company, more than 70% of combined Medicare, Medicaid and commercial insurance lives had formal coverage policies for LIFYORLI in place as of the call. The National Comprehensive Cancer Network listed the therapy as a preferred regimen 15 days after its approval, Corcept said. Vieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI's U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff. He said the combination significantly delayed disease progression and extended overall survival compared with nab-paclitaxel alone. The company reported a 35% reduction in the risk of death, corresponding to a hazard ratio of 0.65 and a P value of 0.0004. Cushing's syndrome demand and relacorilant regulatory update. Korlym and authorized generic product revenue totaled $208.6 million during the quarter. Sean Maduck, president of Corcept's endocrinology division, said the company recorded a record number of new prescriptions, first-time prescribers and patients receiving its Cushing's syndrome medications. Discover more Derivatives Stock Screener Tool Maduck attributed growth to increased physician awareness of hypercortisolism, which can contribute to difficult-to-treat diabetes and resistant hypertension. He cited the company's CATALYST and MOMENTUM studies, which found hypercortisolism in portions of patients screened for those conditions. In response to analyst questions, Maduck said the specialty-pharmacy transition is behind the company and that second-quarter growth was not primarily driven by clearing a backlog. Rather, he said performance reflected continued service of existing patients and a record number of new enrollments. Belanoff said the FDA accepted Corcept's resubmitted new drug application for relacorilant in Cushing's syndrome and assigned a Prescription Drug User Fee Act date of Dec. 17, 2026. Corcept resubmitted the application June 17 after the FDA requested additional analyses of the data from the company's original application during an April meeting. The application is supported by the Phase III GRACE trial and evidence from the Phase III GRADIENT trial, a long-term extension study and earlier development work, Belanoff said. He said the company believes relacorilant demonstrated durable improvement in signs and symptoms of Cushing's syndrome without certain serious adverse events associated with currently approved medications. Pipeline studies continue across cancer, MASH and ALS. Corcept is evaluating relacorilant with chemotherapy in several solid tumors. Belanoff said one arm of the BELLA study in platinum-resistant ovarian cancer is expected to produce results this year, while additional BELLA arms in platinum-sensitive ovarian cancer and endometrial cancer, along with the STELLA cervical cancer trial and TRIDENT first-line pancreatic cancer trial, are expected to report results by the end of 2027. The company also initiated the Phase Ib SYNERGY study of nenicorilant with nivolumab across a range of solid tumors, with results expected by the end of next year. Outside oncology, Corcept said its 175-patient Phase IIb MONARCH study of miricorilant in metabolic dysfunction-associated steatohepatitis, or MASH, has completed enrollment and is expected to produce data later this year. Positive results could support advancement to Phase III, Belanoff said. For ALS, the company is conducting a dose-titration study of dazucorilant to improve gastrointestinal tolerability ahead of a planned pivotal trial expected to begin early next year. Belanoff cited Phase II DAZALS results showing reduced risk of death among patients receiving the 300-milligram dose, while noting that non-serious gastrointestinal distress accounted for most treatment discontinuations. About Corcept Therapeutics (NASDAQ:CORT). Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs. The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Corcept Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list. While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Wolfe Research reiterates "underperform" Rating for Corcept Therapeutics (NASDAQ:CORT). July 27, 2026 Key points. * Wolfe Research reiterated its "Underperform" rating on Corcept Therapeutics and set a $50 price target, implying roughly 47.6% downside from the stock's $95.36 opening price. * Analyst sentiment remains mixed but leans positive overall: MarketBeat reports a consensus rating of "Moderate Buy" and an average price target of $92.17, with targets ranging as high as $135. * Corcept's latest quarterly results missed expectations, with a $0.30 loss per share versus a projected $0.11 loss and revenue of $164.9 million versus $185.83 million expected. Insiders have also sold 300,000 shares worth about $22.1 million over the last quarter. * Five stocks we like better than Corcept Therapeutics. Corcept Therapeutics (NASDAQ:CORT - Get Free Report)'s stock had its "underperform" rating reissued by research analysts at Wolfe Research in a research report issued on Monday,Benzinga reports. They currently have a $50.00 price objective on the biotechnology company's stock. Wolfe Research's price target would suggest a potential downside of 47.57% from the stock's current price. Several other equities analysts have also issued reports on CORT. Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $110.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, May 28th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Zacks Research upgraded shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, May 4th. Piper Sandler boosted their target price on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, May 1st. Finally, UBS Group set a $135.00 target price on shares of Corcept Therapeutics in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $92.17. Corcept Therapeutics stock performance. Shares of CORT opened at $95.36 on Monday. The stock has a market capitalization of $10.24 billion, a P/E ratio of 272.46 and a beta of 0.47. The firm's fifty day simple moving average is $80.40 and its two-hundred day simple moving average is $54.61. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $97.63. Discover more ETF Screener Tool Company News MarketBeat All Access Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). The business had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business's revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.17 earnings per share. As a group, research analysts predict that Corcept Therapeutics will post 0.53 EPS for the current fiscal year. Insiders place their bets. In other news, Director David L. Mahoney sold 20,000 shares of the company's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the transaction, the director directly owned 26,147 shares of the company's stock, valued at $2,210,205.91. This represents a 43.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Guyer sold 20,000 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total value of $1,862,600.00. Following the completion of the transaction, the insider owned 3,985 shares in the company, valued at approximately $371,123.05. This represents a 83.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 300,000 shares of company stock valued at $22,088,050. 20.70% of the stock is currently owned by corporate insiders. Institutional inflows and outflows. Institutional investors have recently bought and sold shares of the business. Advisory Services Network LLC acquired a new position in shares of Corcept Therapeutics during the third quarter valued at about $25,000. Larson Financial Group LLC raised its holdings in shares of Corcept Therapeutics by 2,326.3% in the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 442 shares during the last quarter. Gould Capital LLC lifted its position in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock valued at $50,000 after acquiring an additional 200 shares in the last quarter. Torren Management LLC bought a new position in Corcept Therapeutics in the 4th quarter valued at about $25,000. Finally, CIBC Private Wealth Group LLC boosted its stake in Corcept Therapeutics by 128.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 433 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company's stock. Corcept Therapeutics company profile. Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs. The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Corcept Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list. While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.